Literature DB >> 12504560

The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells.

Chengjun Mo1, Jay Lee, Marvin Sommer, Charles Grose, Ann M Arvin.   

Abstract

The glycoprotein E (gE) of varicella zoster virus (VZV), encoded by ORF68, is the most abundant viral glycoprotein. In the current experiments, we demonstrated that ORF68 deletion was incompatible with recovery of infectious virus from VZV cosmids. Replacing ORF68 at a nonnative AvrII site in the genome restored infectivity. Further, we found that VZV gE could be expressed under the control of the Tet-On promoter in stably transfected melanoma cell lines (Met-gE cells) without evidence of toxicity. In these Met-gE cells, gE colocalized with gamma-adaptin, a trans Golgi network marker, in perinuclear sites, but did not reach plasma membranes. In order to investigate how infection altered gE localization, we made a recombinant virus, vOka-MSPgE, with ORF68 from the VZV MSP strain. VZV MSP encodes a mutant gE protein (D150N) that lacks the mAb epitope, 3B3 (Santos et al., Virology 275, 306-317, 2000), whereas Met-gE protein binds mAb 3B3. Within 48 h after Met-gE cells were infected with vOka-MSPgE, the steady-state distribution of Met-gE protein extended beyond the perinuclear areas to other cytoplasmic sites and to plasma membranes. A second recombinant, vOka-MSPgE without gI (vOka-MSPgEdeltagI), was constructed to investigate Met-gE protein distribution in the absence of gI. The redistribution of Met-gE protein which was observed by 48 h after vOka-MSPgE infection did not occur until 5 days (140 h) within vOka-MSPgEdeltagI infected cells. After vOka-MSPgE infection of Met-gE cells, most Met-gE protein was in the final 94K mature form by 72 h. However, progression to predominance of mature gE was delayed in Met-gE cells infected with vOka-MSPgEdeltagI. These observations confirm our hypothesis that VZV gE is essential, based upon the demonstration of restored infectivity after replacing ORF68 in a nonnative site in the genome, and provide further evidence of the role of gI in facilitating the maturation and intracellular distribution of this critical VZV glycoprotein. Copyright 2002 Elsevier Science (USA)

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12504560     DOI: 10.1006/viro.2002.1556

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  36 in total

1.  Essential functions of the unique N-terminal region of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the pathogenesis of skin infection.

Authors:  Barbara Berarducci; Minako Ikoma; Shaye Stamatis; Marvin Sommer; Charles Grose; Ann M Arvin
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

Review 2.  Varicella-Zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model.

Authors:  Chia-Chi Ku; Jaya Besser; Allison Abendroth; Charles Grose; Ann M Arvin
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

3.  The extracellular domain of herpes simplex virus gE is indispensable for efficient cell-to-cell spread: evidence for gE/gI receptors.

Authors:  Katarina Polcicova; Kim Goldsmith; Barb L Rainish; Todd W Wisner; David C Johnson
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 4.  A critical appraisal of 'Shingrix', a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus.

Authors:  Tehmina Bharucha; Damien Ming; Judith Breuer
Journal:  Hum Vaccin Immunother       Date:  2017-04-20       Impact factor: 3.452

5.  The insulin degrading enzyme binding domain of varicella-zoster virus (VZV) glycoprotein E is important for cell-to-cell spread and VZV infectivity, while a glycoprotein I binding domain is essential for infection.

Authors:  Mir A Ali; Qingxue Li; Elizabeth R Fischer; Jeffrey I Cohen
Journal:  Virology       Date:  2009-02-23       Impact factor: 3.616

6.  Myelin-associated glycoprotein mediates membrane fusion and entry of neurotropic herpesviruses.

Authors:  Tadahiro Suenaga; Takeshi Satoh; Pranee Somboonthum; Yasushi Kawaguchi; Yasuko Mori; Hisashi Arase
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

7.  Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-zoster virus infection.

Authors:  Barbara Berarducci; Jaya Rajamani; Leigh Zerboni; Xibing Che; Marvin Sommer; Ann M Arvin
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

8.  Varicella-zoster virus infection of human neural cells in vivo.

Authors:  Armin Baiker; Klaus Fabel; Antonio Cozzio; Leigh Zerboni; Konstanze Fabel; Marvin Sommer; Nobuko Uchida; Dongping He; Irving Weissman; Ann M Arvin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-09       Impact factor: 11.205

9.  Cholesterol dependence of varicella-zoster virion entry into target cells.

Authors:  S Hambleton; S P Steinberg; M D Gershon; A A Gershon
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

10.  Development of recombinant varicella-zoster viruses expressing luciferase fusion proteins for live in vivo imaging in human skin and dorsal root ganglia xenografts.

Authors:  Stefan L Oliver; Leigh Zerboni; Marvin Sommer; Jaya Rajamani; Ann M Arvin
Journal:  J Virol Methods       Date:  2008-09-24       Impact factor: 2.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.